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ACTR (also called AIB1 and SRC-3) was identified as a coactivator for nuclear receptors and is linked to
multiple types of human cancer due to its frequent overexpression. However, the molecular mechanism of
ACTR oncogenicity and its function independent of nuclear receptors remain to be defined. We demonstrate
here that ACTR is required for both normal and malignant human cells to effectively enter S phase. RNA
interference-mediated depletion and chromatin immunoprecipitation assays show that endogenous ACTR
directly controls the expression of genes important for initiation of DNA replication, which include cdc6,
cdc25A, MCM7, cyclin E, and Cdk2. Moreover, consistent with its critical role in cell cycle control, ACTR
expression appears to be cell cycle regulated, which involves E2F. Interestingly, ACTR is recruited to its own
promoter at the G1/S transition and activates its own expression, suggesting a positive feedback mechanism for
ACTR action in the control of cell cycle progression and for its aberrant expression in cancers. Importantly,
overexpression of ACTR alone transforms human mammary epithelial cells, which requires its association with
E2F. These findings reveal a novel role for ACTR in cell cycle control and support the notion that the ability
of aberrant ACTR to deregulate the cell cycle through E2F underlies its oncogenicity in human cancers.
The mammalian cell cycle involves a dynamic transcriptional
control program responsible for the timely expression of key
cyclins, cdks, and proteins with functions in DNA synthesis and
replication. This program is mediated primarily by members of
the E2F family, which are encoded by eight distinct E2F genes.
Recent studies have provided evidence that E2F1, -2, and -3
function primarily as transcriptional activators while E2F4 to
-8 act as repressors (2, 7, 11, 30, 33, 38, 56). These transcrip-
tional regulation activities of E2Fs are likely mediated by dis-
tinct groups of nuclear cofactors. Indeed, strong evidence sug-
gests important roles played by enzymatic complexes of
chromatin modification and remodeling in transcriptional si-
lencing of E2F target genes (13, 20). Thus, in quiescent cells
E2Fs associate with hypophosphorylated pocket proteins
(pRb, p107, and p130), and together they recruit the enzymatic
complexes, such as histone deacetylases, the Brg1 chromatin-
remodeling complex, and histone methyltransferases, to re-
press certain cell cycle genes, such as cyclin E, cyclin A, and
cdc2 (1, 24, 29, 39–42, 52). Once cells reenter the cell cycle,
hyperphosphorylation of pocket proteins leads to their disso-
ciation from E2Fs and disassembly of the corepressor complex.
Much less is understood about the subsequent process of
transcriptional activation by E2Fs. Based on biochemical anal-
ysis and reporter gene assay, a number of cofactors, including
p300, CBP, and PCAF, have been implicated in the process of
E2F-mediated transactivation (34, 57). However, evidence of
their direct involvement in controlling key cell cycle gene ex-
pression has not yet been presented, suggesting the existence
of other E2F coactivators. In this regard, it has recently been
demonstrated that components of the TRRAP (transactiva-
tion-transformation domain-associated protein)/Tip60/GCN5
histone acetyltransferase complexes are required for cell pro-
liferation and recruited to a subset of E2F target gene promot-
ers, supporting the notion that distinct chromatin modifying-
remodeling complexes might be participating in activation of
different groups of E2F target genes (26, 27, 54).
ACTR (activator of thyroid and retinoid receptors), also
named AIB1 (amplified in breast cancer 1) and SRC-3 (steroid
receptor coactivator 3), is a member of the p160/SRC tran-
scriptional coregulator family (18, 35, 49). Like other p160s,
ACTR was identified as a nuclear cofactor that associates with
hormone-bound nuclear receptors and mediates the transcrip-
tional activation function of the receptors. The p160s contain
functional domains for interactions with receptors, the coregu-
lator proteins CBP and p300, PCAF, and arginine methyltrans-
ferases (51). It is generally accepted that the p160s are re-
cruited to hormone-responsive genes through their interaction
with activated receptors and then nucleate the assembly of a
coactivator complex, which in turn remodels chromatin through
histone modifications and facilitates RNA polymerase II (Pol II)
transcription.
ACTR is linked to cancer because of its frequent amplifica-
tion and/or overexpression. Although the initial analysis sug-
gested a correlation between ACTR amplification and positive
estrogen receptor (ER) status, later studies found that over-
expression of ACTR in breast cancers does not correlate with
positive ER status (3). In fact, more clinical studies have re-
vealed the aberration of ACTR in a broad spectrum of malig-
nancies with high frequency, including pancreatic adenocarci-
noma, hepatocellular carcinoma, gastric cancers, esophageal
squamous cell carcinoma, and prostate cancer (14, 19, 21, 46,
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59, 67). Despite these clinical studies, little was known about
how elevated ACTR may induce tumorigenesis and/or pro-
mote tumor growth. By crossing SRC-3 (the mouse ortholog of
ACTR) knockout mice with MMTV-v-Ha-ras transgenic mice,
it was recently demonstrated that ACTR is required for onco-
genic ras-induced mammary tumorigenesis (25). Interestingly,
deletion of ACTR did not affect the promotional role of ovar-
ian hormones in mammary tumor formation or the hormone-
responsive gene expression in the mammary gland, suggesting
that ACTR and estrogens contribute to mammary carcinogen-
esis through different mechanisms. Another study showed that
overexpression of ACTR in multiple tissues of mice resulted in
many types of malignancy, including tumor formation in the
mammary gland, pituitary, uterus, lung, liver, and skin, indi-
cating that aberrant ACTR can act as an oncogene in vivo (55).
Although defects or abnormal activity in IGF-1-mediated sig-
naling were observed in these studies, it is unclear whether
deregulation of the IGF-1 pathway is the primary molecular
underpinning of aberrant ACTR-induced tumorigenesis.
In our attempt to determine the potential role of ACTR in
the control of breast cancer cell proliferation, we found that
silencing ACTR expression inhibits the proliferation of ER-
positive and -negative breast cancer cells and that overexpres-
sion of ACTR negates the growth-inhibitory effect of anties-
trogens (32). Through functional analysis, we uncovered that
ACTR directly interacts with E2F1 and that ectopically ex-
pressed ACTR up-regulates key cell cycle genes, including
those for cyclin E1, cyclin A2, cdk2, and E2F1. We report here
that endogenous ACTR directly controls the expression of
genes critical for initiation of DNA replication and is required
for effective G1-S progression of both normal and malignant
human cells. Surprisingly, we found that ACTR gene transcrip-
tion appears to be cell cycle regulated, which involves an
ACTR-E2F complex. More importantly, we found that ele-
vated ACTR transforms nonmalignant human breast epithelial
cells independently of the ER but dependent on its ability to
associate with E2Fs.
MATERIALS AND METHODS
RNA interference (RNAi), recombinant adenovirus vectors, and plasmid con-
structs. Small interfering RNA (siRNA) oligonucleotides specifically targeting
ACTR and control RNA oligonucleotides were synthesized by Dharmacon with
the following sequences: siACTR, 5-GGUCUUACCUGCAGUGGUGAAdTd
T-3 (sense) and 5-UUCACCACUGCAGGUAAGACCdTdT-3 (antisense);
control siRNA, 5-CCAUGAGUCACGCAUCCAAGCdTdT-3(sense) and 5-
GCUUGGAUGCGUGACUCAUGGdTdT-3 (antisense). Adenoviral vectors
expressing ACTR, GFP, or ACTR-siRNA and GFP-siRNA were created as
previously described (32). In brief, for RNAi vector construction, the human H1
gene promoter sequence was inserted into the pShuttle plasmid from the Adeasy
system. Oligodeoxynucleotides containing coding sequences for siRNA targeting
ACTR (5GGTCTTACCTGCAGTGGTGAA) and green fluorescent protein
(GFP) (5GAACTTCAGGGTCAGCTTG) were inserted downstream of the H1
promoter. The resulting pShuttle-RNAi constructs were then used to generate
recombinant adenoviruses. Viral particles were purified by centrifugation in a
CsCl step gradient. Viral titers were determined by endpoint cytopathogenic
effect assay and/or with the anti-hexon antibody-based Adeno-X rapid titer kit
(BD Biosciences).
Based on the sequence information at the National Center for Biotechnology
Information EvidenceViewer for human ACTR/NCOA3, a genomic DNA frag-
ment (1.6 kb, HindIII-NcoI) containing the first exon of ACTR was amplified by
Pfu polymerase from human prostate cancer cell line LNCaP cells and inserted
into vector pGL3-basic (Promega) to generate ACTR promoter luciferase re-
porter pGL3-ACTR-1.6kb. The pGL3-ACTR-0.6kb plasmid was constructed by
inserting into pGL3 the 0.6-kb BamHI-BamHI fragment contained in the 1.6-kb
genomic DNA. Wild-type and mutant pSh-HCMV-ACTR plasmids were de-
scribed before (32).
Cell proliferation, anti-BrdU (bromodeoxyuridine) staining, and fluores-
cence-activated cell sorter (FACS) analysis of the cell cycle. Human diploid
fibroblasts (IMR-90 and WI38) were obtained from the American Type Culture
Collection (ATCC) and maintained in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS; Gemini) and anti-
biotics. Early passages of the fibroblasts (105) were plated in six-well plates and
infected 24 h later with adenovirus vectors expressing ACTR-siRNA or GFP-
siRNA at an MOI (multiplicity of infection) of 50. Cells were refed with fresh
medium every 2 days. Cell proliferation was measured every 2 days by cell
numeration of triplicates of coded samples. Parallel samples were also harvested
for analysis of cell cycle distribution by staining with propidium iodide and flow
cytometry by FACScan (Coulter). For anti-BrdU staining, IMR-90 cells (105)
were plated in six-well plates containing untreated glass slides (Fisher) and
infected 24 h later as described above. Cells were then maintained in medium
containing 0.1% FBS for 3 days, replenished with 10% FBS, and maintained for
another 24 or 48 h. One hour before harvesting, cells were pulse-labeled for 60
min with 10 M BrdU (Roche). Cells were fixed in 70% ethanol and then treated
with 2 N HCl and 0.5% Triton X-100 for 10 min. After washing with phosphate-
buffered saline, the slides were incubated with a 1:50 dilution of anti-BrdU–
fluorescein isothiocyanate (FITC) antibody (Roche) for 1 h. Cells were washed
in phosphate-buffered saline and counterstained with 4,6-diamidino-2-phe-
nylindole (DAPI) for 3 min. FITC and DAPI signals were detected by fluores-
cence microscopy, and digital images were recorded. The percentage of BrdU-
positive cells was determined by counting the BrdU-positive cells in five different
frames and dividing by the total number of DAPI-positive cells. Results repre-
sent averages of two independent experiments.
MCF10A cells were obtained from the ATCC and maintained in mammary
epithelial growth medium with supplements from BioWhittaker or in DMEM/
F12 supplemented with 2% horse serum (Invitrogen), 1 g of insulin per ml, 1
ng of cholera toxin per ml, 100 g of hydrocortisone per ml, and 10 ng of human
epidermal growth factor. For cell proliferation assay, MCF10A cells maintained
in six-well plates in DMEM/F12 with the supplements described above (as full
supplements) were infected with the ACTR- or GFP-adenovirus vectors at equal
MOIs. Four hours later, the medium was changed to DMEM/F12 with 0.1% of
the full supplements. On different days after infection, cells were harvested for
proliferation analysis by cell enumeration in triplicate.
Soft-agar colony formation assay. MCF10A cells maintained in mammary
epithelial growth medium with full supplementation were infected at 70% con-
fluence with the adenovirus vectors as described above. Twenty-four hours after
infection, cells were detached from the plates by trypsinization. Cells were
resuspended as individuals in DMEM/F12 growth medium with the full supple-
ments described above mixed at a 3:1 ratio with 1.6% agarose (SeaPlaque;
BioWhittaker). The mixture was then plated onto six-well plates at 5  104
cells/well over a bottom layer of 0.8% agarose in DMEM/F12 with the supple-
ments. Cells were maintained at 37°C with a medium change every 3 days. Two
weeks later, cell aggregates with diameters of 0.2 mm or larger (containing
approximately 50 or more cells) were counted as colonies. The entire experiment
was repeated once.
Transfection and reporter gene assay. HeLa and human glioblastoma T98G
cells were obtained from the ATCC and maintained in DMEM plus 10% FBS
and antibiotics. For transfection of synthetic siRNA, HeLa or T98G cells were
plated into six-well plates and transfected at 30 to 40% confluence with 250 pmol
(2 g) of duplex siRNA with Oligofectamine (Invitrogen) following the manu-
facturers’ protocol. Cells were then maintained in DMEM plus 5% charcoal-
stripped FBS and harvested at different time points for cell proliferation (cell
enumeration of triplicate coded samples), Western blotting, or RNA extraction.
Reporter gene assay was performed with adenovirus E1A-transformed human
embryonic retina (HER) cells as described previously (32), except that firefly
luciferase reporter activity was normalized with -galactosidase activity via co-
transfection of plasmid pCMX--gal (8). HER cells can be readily transfected
with Lipofectamine (Invitrogen), achieving 80 to 90% efficiency. Each transfec-
tion was performed in triplicate.
Western blotting and quantitative reverse transcription (RT)-PCR analysis.
Whole-cell lysates were prepared from cells treated and harvested as indicated in
buffer containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 10% glycerol, 0.5%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 1 protease inhibitor
cocktail (Promega). Western blotting analysis of proteins separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis was performed with specific
antibodies as described previously (32) and monoclonal antibodies from Santa
Cruz against Cdc6 (180.2), Cdc25A (F-6), PCNA (PC10), and MCM7 (141.2).
For semiquantitative RT-PCR analysis of gene expression, 3 g of total RNA
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was used for an RT reaction with Moloney murine leukemia virus reverse
transcriptase and oligo(dT)18 primers. cDNAs were diluted 10-fold, and 5 l was
used for the PCRs (25 to 28 cycles). The sequences of the primers used for
RT-PCR are listed in Table 1. Quantitative RT-PCR was performed as previ-
ously described (32).
Cell cycle synchronization and chromatin immunoprecipitation (ChIP). T98G
cells grown to 60% confluence were serum starved for 3 days in DMEM con-
taining 0.1% FBS. Cells were then released to the cell cycle by changing to
medium containing 20% FBS. Alternatively, overnight after plating in regular
growth medium (DMEM containing 10% FBS), cells were treated with 2 mM
hydroxyurea for 18 h and then washed three times with the regular growth
medium containing 2 M nocodazole and incubated in the same medium for
12 h. Cells were released to the cell cycle by washing three times with drug-free
growth medium. Cells were harvested at specified time points after the medium
change for flow cytometric analysis of cell cycle distribution, gene expression
analysis, or ChIP assay by fixing in 1% formaldehyde for 8 min. ChIP assays were
performed essentially as described previously (31). The crude chromatin solution
was diluted and incubated overnight at 4°C with specific antibodies (25 l of
anti-ACTR [9], 5 g of anti-E2F1 [1:1 mixture of C-20 and KH95; Santa Cruz],
5 g of anti-rabbit immunoglobulin G [Santa Cruz], and 35 l of anti-RNA Pol
II (8WG16; Covance). PCR with 28 cycles was performed with 5 to 10 l of
purified ChIP DNA with promoter-specific primers. The sequences of the prim-
ers used are shown in Table 1. Representative gel pictures or quantified PCR
products from three independent experiments are presented.
RESULTS
ACTR is required for proliferation of both normal and ma-
lignant human cells. Our previous study with breast cancer cells
demonstrated that ACTR overexpression abrogates the growth-
inhibitory effect of antiestrogens. To determine whether endoge-
nous ACTR functions similarly in other cell types, including non-
malignant cells, we examined the effect of acute ACTR depletion
on the proliferation of a panel of different cell types. As shown in
Fig. 1A, adenoviral vector-mediated RNAi specifically prevented
expression of the ACTR protein, but not the other p160 member
TIF2, in IMR-90 diploid human fibroblasts 2 days after viral
vector treatment. Examination of IMR-90 cells treated with the
vectors indicated that depletion of ACTR resulted in a marked
inhibition of cell proliferation, which lasted for a week (Fig. 1B),
while no effect was observed with cells treated with RNAi-GFP,
compared to mock-treated cells. Similar results were obtained
with diploid fibroblast WI-38 cells (data not shown). To further
extend the analysis, we examined the effect of ACTR knockdown
on the proliferation of malignant cells such as HeLa and T98G.
Proliferation of these cells is not responsive to stimulation by
hormones such as estrogen and androgen. Knocking down the
high endogenous levels of ACTR strongly reduced the prolifera-
tion rate of both HeLa and T98G cells (Fig. 1C). Together, these
results indicate that ACTR is required for the proliferation of
both normal and malignant human cells that are nonresponsive to
hormonal stimulation and are derived from different tissues.
ACTR depletion strongly impedes cell entry into S phase.
Next, we wish to understand whether ACTR is involved in
promoting cell proliferation by controlling cell cycle progres-
sion. Asynchronously proliferating IMR-90 cells were infected
with the adenoviral vector for ACTR depletion and harvested
at different times for analysis of cell cycle distribution by flow
cytometry. As shown in Fig. 2A, 48h after infection, cells
treated with adenovirus ACTR RNAi showed a significant
decrease in the S-phase cell population (from 27% at 12 h to
10% at 48 h) with a concomitant increase in the number of
G1-phase cells (from 53% at 12 h to 67% at 48 h), while cells
mock treated or treated with adenovirus GFP-RNAi displayed
no significant change in cell cycle distribution between the two
points. Interestingly, a slight increase in the percentage of cells
in G2/M phase was also observed in adenovirus ACTR RNAi-
treated cells (from 19.7% at 12 h to 22.9% at 48 h), suggesting
that ACTR may also play a role in G2/M. To directly assess the
function of ACTR in G1-to-S progression, we examined the
effect of ACTR depletion on DNA synthesis in synchronized
cells. Cells were first deprived of serum for arrest at G1/G0 and
infected with the adenovirus RNAi, released to reenter the cell
TABLE 1. Nucleotide sequences of the PCR primers used in this study






















a UTR, untranslated region.
b GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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cycle, and pulse-labeled with BrdU. Figure 2B and C show that
at 48 h after adenovirus RNAi treatment, while cells treated
with the control GFP-RNAi adenovirus vector had about 26%
BrdU-positive cells, cells treated with the ACTR-RNAi ade-
novirus vector had only about 7% BrdU-positive cells. Taken
together, these results suggest that ACTR depletion strongly
impedes the DNA synthesis of IMR-90 cells.
ACTR is required for the expression of genes with critical
functions in DNA replication. The above finding that ACTR is
required for G1-to-S progression prompted us to examine
whether ACTR is required for expression of genes that are
crucial for cell cycle progression. Given the observation we
made previously that ACTR associates with activator E2Fs, we
focused our analysis on key cell cycle genes with expression
regulated by E2Fs. As shown in Fig. 3A, depletion of ACTR in
IMR-90 cells resulted in a significant reduction of cyclin A2,
cdk2, cdc2, and E2F1 expression at both the mRNA (part b)
and protein (part a) levels. The effect on the mRNA level can
be observed as early as 24 h after adenovirus ACTR RNAi
treatment. Notably, cyclin D1 was not affected by ACTR de-
pletion. We then extended our study to HeLa and T98G cells
and observed a similar effect of ACTR depletion on the ex-
pression of cyclin E, cdk2, and E2F1, but not on that of cyclin
A2 (Fig. 3B and data not shown).
DNA replication in eukaryotic cells involves timely expres-
sion and assembly of multiple protein complexes. The expres-
sion of a number of genes, including those for cdc6, cdc25A,
and MCMs, is induced at late G1 and is regulated by E2Fs. We
FIG. 1. ACTR is required for the proliferation of normal and cancerous human cells. (A and B) Depletion of ACTR inhibits the proliferation
of diploid human fibroblast cells. IMR-90 cells were infected 24 h after plating with equal MOIs of adenoviral vectors expressing ACTR siRNA
(Ai) or GFP siRNA (Gi) or mock infected (M). Cells were harvested 2, 4, and 6 days after infection for Western blotting (A) or cell proliferation
(B). Four days after infection, cells were fixed with 70% ethanol and stained with crystal violet before digital images of representative fields of cells
were taken. (C) Depletion of ACTR inhibits the proliferation of HeLa and T98G cells. Cells growing in six-well plates were transfected with
synthetic siRNA targeting ACTR (ACTR-Ri) or control siRNA (Control-Ri). On different days after transfection, cells were harvested and
counted in triplicates. Western analysis was performed with cell lysates harvested 2 days after transfection.
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thus wished to determine whether inhibition of DNA synthesis
by ACTR depletion resulted from suppressed gene expressions
critical for initiation of DNA replication. Results in Fig. 3B
indicate that, indeed, depletion of ACTR caused a two- to
fivefold decrease in cdc6, cdc25A, and MCM7 transcripts and
their proteins. Interestingly, the expression of RFC3, PCNA,
MCM10, cdc45, and TopBP1 was not affected under the same
conditions (Fig. 3B and data not shown), suggesting that
ACTR is required for a subset of E2F target genes involved in
DNA replication of HeLa cells.
Endogenous ACTR is recruited to a subset of E2F target
genes at G1/S. Having found that endogenous ACTR is re-
quired for the expression of a subgroup of cell cycle genes, we
sought to determine whether ACTR is directly involved in
transcriptional control of their expression by examining the
promoter occupancy of ACTR. We thus performed ChIP as-
says with T98G cells that can be readily rendered quiescent
and progress synchronously through the cell cycle (53). In
agreement with the results from ACTR depletion, we found
that endogenous ACTR protein is recruited to a region con-
taining E2F binding sites on the promoters of cdk2, E2F1,
cdc6, cdc25A, and MCM7 (Fig. 4). Importantly, the recruit-
ment is increased significantly (three- to fourfold, depending
on the target genes) as the cells enter S phase. Similar induc-
tion of recruitment is observed with E2F1. Consistent with the
findings that E2F4 primarily plays a repressor role at early G1
(53), the occupancy of E2F4 decreases as cells start to prolif-
erate. The fact that ACTR does not occupy promoters of genes
with expression unaffected by ACTR depletion, such as
TopBP1 and caspase 9 (Fig. 4 and data not shown), indicates
that the observed induction of ACTR recruitment is promoter
specific and not a simple reflection of its elevated expression
during cell cycle progression (details are described below).
ACTR expression is cell cycle regulated. Overexpression of
ACTR has been detected in many types of human cancers.
However, how ACTR expression is regulated remains un-
known. In our examination of gene expression with cells syn-
chronized in cell cycle progression, we noticed that ACTR
expression fluctuates. We therefore set up experiments to de-
termine whether ACTR gene expression is regulated in a cell
cycle-dependent manner. First, we examined ACTR expres-
sion in T98G cells during their synchronous cell cycle progres-
sion. After being released from serum deprivation, fractions of
cells were analyzed for cell cycle progression and for gene
expression by semiquantitative RT-PCR and Western analysis.
Data from flow cytometry analysis (Fig. 5A, top part) show that
cells began to enter S phase around 18 h after being released
from G1/G0 and progressed through S phase during the next
6 h, as indicated by an increase in the S-phase cell population
from 6.7% to 26% at the 18-h point and a further increase to
nearly 90% at the 24-h point. The synchronous cell cycle pro-
gression is also evidenced by the oscillation of cyclin E1 and A2
levels, as well as the timely hyperphosphorylation of pocketFIG. 2. ACTR depletion blocks cell entry into S phase. (A) IMR-90
cells were infected with RNAi adenovirus vectors targeting ACTR
(ACTR-Ri) or GFP (GFP-Ri) or mock infected and harvested 12, 24, 36,
and 48 h after infection. Fixed cells were stained with propidium iodide.
Cell cycle profiles were determined by flow cytometry. (B and C) IMR-90
cells were infected with RNAi adenovirus vectors, deprived of serum for
arrest at G1/G0, released to reenter the cell cycle, and then pulse-labeled
with BrdU for 1 h before being harvested. Cells were first stained with
anti-BrdU–FITC and then counterstained with DAPI. Results in panel B
represent the 48-h time point, showing the same field of cells stained with
DAPI or anti-BrdU–FITC. The percentage of BrdU-positive cells in
panel C was determined by counting the BrdU-positive cells in five
frames and dividing by the total number of DAPI-positive cells. Re-
sults represent averages of two independent experiments.
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protein p130 (indicated by the band upshifts at the 12- and
18-h points, bottom part), as p130 is usually hyperphosphory-
lated by cyclin/Cdk complexes at late G1. Strikingly, ACTR
expression was strongly up-regulated at mRNA level in late G1
at the 12-h point (middle part), with its protein level peaking at
G1/S around the 18-h point (bottom part). Interestingly,
ACTR expression was sharply attenuated after cells entered S
phase. Such induction kinetics of ACTR was also observed
with IMR-90 cells and closely mimics that of its interacting
proteins, such as E2F1 and E2F3, but not that of TIF2, P/CAF,
and CBP (Fig. 5A and data not shown).
To rule out the possibility that the change in ACTR expres-
FIG. 3. Depletion of ACTR inhibits the expression of cdc25A, cdc6, and MCMs, as well as cyclins and Cdk. (A) IMR-90 cells were infected
with RNAi adenovirus vectors as in Fig. 1A and harvested at different times after infection for Western blotting (part a) or semiquantitative
RT-PCR analysis (part b). The relative transcript levels are presented as arbitrary units of PCR products quantified by the Fluorchem software
for cells treated with adenovirus vectors of ACTR-RNAi (open bars) or GFP-RNAi (filled bars). (B) HeLa cells were transfected with synthetic
siRNA targeting either ACTR (ACTR-Ri) or a control RNAi oligonucleotide (Control-Ri) and harvested 48 later for Western blotting (part a)
or 48 and 72 h later for quantitative RT-PCR, with the value from control RNAi set as 100 (part b). No significant difference in expression is
illustrated by the gel image of semiquantitative RT-PCR products.
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sion is due to the effect of growth factors in the serum and to
confirm that ACTR is indeed cell cycle regulated, we synchro-
nized cells for cell cycle progression by a protocol without
altering the growth factor or serum in the medium. Thus, we
treated proliferating T98G cells first with hydroxyurea (which
arrests the cell cycle by inhibiting DNA synthesis) to partially
synchronize T98G cells at G1/S and then released them from
the block in the presence of nocodazole, which in turn blocks
cells at metaphase. At different points after the drug was re-
moved, cells were harvested for flow cytometry and gene ex-
pression analysis. As shown in Fig. 5B, top part, 9 to 12 h after
being released from nocodazole treatment, cells exited mitosis
and entered G1-S. At the same time, the expression of ACTR,
like that of E2F1 and cyclin E, was induced to a peak level
(middle and bottom parts), in agreement with the expression
kinetics shown in Fig. 5A. Unlike that of ACTR, the TIF2
protein level did not appear to change. Taken together, these
results suggest that ACTR expression is cell cycle regulated at
the transcript level, peaking at the G1-S boundary.
ACTR promoter is activated by E2F and ACTR itself. To
understand the molecular mechanism underlying cell cycle reg-
ulation of ACTR expression, we first examined its promoter
response to E2F stimulation. Thus, a 1.6-kb genomic DNA
fragment encompassing the first exon of ACTR was isolated
and subcloned upstream of the luciferase reporter gene in
vector pGL3. As shown in Fig. 6A, the resulting construct
displayed strong promoter activity when transfected into pro-
liferating HER cells (compare the reporter activities driven by
pGL3-ACTR-1.6kb with that of 3XE2F-TK-Luc). Similar re-
sults were obtained with a shorter version of the construct,
pGL3-ACTR-0.6kb. Importantly, this ACTR promoter activity
can be markedly stimulated by E2F1 (about 5-fold or 15-fold,
respectively, for the two promoter reporters). Since the 0.6-kb
fragment confers most or all of the responsiveness to E2F
stimulation, we analyzed its sequence with the PROMO data-
base and identified multiple putative, noncanonical E2F1 bind-
ing sites (5-CCGCC/G-3) located in the region between 150
and 360. Similar sequences have recently been demonstrated
to directly bind to E2F1 and mediate its transcriptional re-
sponse (58). In light of our recent finding that ACTR can act
as an E2F coactivator to control E2F target gene expression,
we speculated that ACTR might be involved in the control of
its own promoter via E2F. Results in Fig. 6A show that, indeed,
ACTR significantly enhanced the transcription of its own pro-
moter when tested on either the 0.6-kb or the 1.6-kb reporter
construct. To determine whether ACTR acts on its own pro-
moter through association with E2Fs, we tested the activity of
a mutant form of ACTR that lacks the E2F interaction domain
(EID) in the reporter gene assay. Strikingly, eliminating its
interaction with E2Fs severely diminished the ability of ACTR
to activate its own promoter (Fig. 6B). The mutant ACTR is
expressed at a level similar to that of the wild type (see Fig.
8E). These results suggest that ACTR controls its own pro-
moter through association with E2Fs such as E2F1.
ACTR-E2F complex is recruited to ACTR promoter at late
G1 to stimulate its expression. To address whether the endog-
enous ACTR-E2F complex controls ACTR transcription in a
cell cycle-dependent manner, we examined its occupancy at the
ACTR promoter in cells synchronously progressing through
the cell cycle. T98G cells released from serum starvation were
harvested for ChIP at different times after the release. As
shown in Fig. 7A, quiescent cells (at the 0-h point) had little
FIG. 4. ACTR is recruited to the promoters of E2F target genes at G1/S. T98G cells were synchronized by serum starvation for 3 days in
DMEM containing 0.1% FBS and then released to the cell cycle by changing to medium containing 20% FBS. Cells were harvested for ChIP assay
with the indicated antibodies at 0 (open bars), 12 (gray bars), and 18 (black bars) h after serum readdition. The relative occupancy at the specific
promoters was determined by quantifying the ChIP PCR products obtained from three experiments. The location of the sequence analyzed at each
promoter is indicated. IgG, immunoglobulin G.
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E2F or ACTR occupancy of the ACTR promoter. At 12 h after
cells reentered the cell cycle, the occupancy of the ACTR
promoter by the ACTR-E2F complex was significantly in-
duced. By 18 h, when the majority of cells were at late G1 and
a fraction of cells (24.4%) entered S phase, much stronger
recruitment of the complex was observed. Strikingly, when
most of the cells were in S phase (at 24 h), the ACTR-E2F
occupancy was markedly decreased. This dynamic occupancy
of the ACTR promoter by the ACTR-E2F complex correlates
closely with the kinetics of ACTR gene expression during cell
cycle progression shown in Fig. 5, supporting the notion that
the E2F-ACTR complex plays an important role in cell cycle
regulation of ACTR expression. To confirm that the cell cycle-
regulated recruitment of the E2F-ACTR complex is specific to
the proximal promoter, we examined the occupancy of E2F1,
ACTR, and RNA Pol II over a 10-kb genomic DNA sequence
around the promoter. We found that when T98G cells were at
the G1-S boundary (the18-h point), both E2F1 and ACTR
were recruited primarily to the 1-kb promoter sequence (cov-
ered by amplicons E, F, and G), which encompasses the 0.6-kb
sequence used in the reporter assays (Fig. 7B, left part). Con-
sistent with its strong promoter activity, this 1-kb region dis-
played a robust Pol II occupancy in the proliferating cells, as
detected by the anti-Pol II antibody. Importantly, similar oc-
cupancy by E2F1, ACTR, and Pol II was observed in asynchro-
nously proliferating MCF7 human breast cancer cells (Fig. 7B,
right part), suggesting that ACTR expression is also regulated
by the E2F-ACTR complex in human breast cancer cells. To
examine whether ectopic expression of ACTR can stimulate
endogenous ACTR gene expression in T98G cells, we infected
the cells with an adenovirus vector that expressed only the
coding sequence of ACTR with a hemagglutinin (HA) tag at its
3 end. As shown in Fig. 7C, at 48 h after infection, we ob-
served a significant increase in the expression of the endoge-
nous ACTR gene (detected by its 3 untranslated region se-
quence) in cells infected with the ACTR adenovirus vector
(A), but not with the control GFP-adenovirus vector (G). In-
terestingly, we did not observe any significant effect of ectopic
ACTR expression on the expression of SRC-1, the other mem-
ber of the p160 coactivator family, suggesting that SRC-1 is not
subject to regulation by ACTR under these conditions.
Overexpression of ACTR alone transforms human mam-
mary epithelial cells, which requires its association with E2F.
Having demonstrated that ACTR plays an important role in
the proliferation of a number of cell types and that ACTR
autoregulation may contribute to its overexpression, a critical
question to be addressed is whether ACTR overexpression
alone can elicit any oncogenic effect on nonmalignant human
cells. MCF10A, an ER-negative, spontaneously immortalized,
FIG. 5. Expression of ACTR is induced at late G1 and attenuated
during S phase. (A) T98G cells were synchronized by serum depriva-
tion as for Fig. 4 and harvested at the indicated times after serum
stimulation for flow cytometry, semiquantitative RT-PCR, and West-
ern blot analysis. (B) T98G cells were synchronized in mitosis by
treatment with hydroxyurea and then with nocodazole. Cells were
released to reenter the cell cycle by switching to nocodazole-free
growth medium. Cells were harvested at the indicated times after
release for analyses as in panel A. As, asynchronous proliferating cells.
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nontransformed human mammary epithelial cell line, has been
widely used to assess the oncogenic activity of many oncogenes
in in vitro cell transformation assays (10, 37, 43, 45). First, to
determine whether ACTR regulates its own expression in
MCF10A cells, we performed a ChIP assay to examine the
occupancy by ACTR and E2F1 at the ACTR promoter with
proliferating MCF10A cells maintained either in medium with
the full (100%) growth factor supplements or changed to me-
dium with 0.1% of the full supplements and maintained for 6 h.
As shown in Fig. 8A, strong occupancy by ACTR and E2F1
was detected at the ACTR promoter when cells were prolifer-
ating in the medium with full supplements, indicating that
ACTR and E2F1 are indeed involved in the control of ACTR
expression in MCF10A cells. Interestingly, deprivation of the
growth factors reduced their occupancy, suggesting that the
recruitment of ACTR and E2F1 to the ACTR promoter in
MCF10A cells is stimulated by growth factors. Next, we exam-
ined whether ACTR overexpression stimulates growth factor-
independent cell proliferation. MCF10A cells maintained in
medium with full supplements were infected with the ACTR-
or GFP-adenovirus vector. After infection, cells were essen-
tially deprived of growth factors (maintained in 0.1% of the full
supplements). As shown in Fig. 8B, at 2 days after growth
factor deprivation, proliferation of cells infected with the con-
trol GFP-adenovirus vector was essentially stopped. In con-
trast, cells infected with the ACTR-adenovirus vector contin-
ued to proliferate. It is worth noting that when MCF10A cells
were maintained in the medium with full supplements, infec-
tion with the ACTR- or GFP-adenovirus vector did not have
any significant effect on their proliferation (data not show).
These results suggest that high levels of ACTR can stimulate
growth factor-independent proliferation of MCF10A cells.
To examine the activity of ACTR in cellular transformation,
MCF10A cells infected with adenovirus vectors were plated in
soft agar and observed for colony formation. As shown in Fig.
8E, recombinant adenovirus vectors mediates the expression in
MCF10A cells of the wild-type and mutant forms of ACTR (as
diagramed in panel C) at a similar level, when analyzed by
Western blotting with an anti-HA antibody (part a). The level
of ectopically expressed ACTR proteins was about threefold
higher over the endogenous ACTR, judged by the results of
Western blotting with an anti-ACTR antibody (part b; note
that the monoclonal antibody recognizes an epitope within the
E2F interaction domain [EID] and therefore does not detect
ectopically expressed ACTR-EID or -A38). As shown in Fig.
8D and F, at 2 weeks after plating in soft agar, cells overex-
pressing wild-type ACTR displayed a high frequency of colony
formation, while no colony was observed with control cells
expressing GFP. Strikingly, cells expressing ACTR mutant
forms that lack the E2F-interaction domain (ACTR-EID or
FIG. 6. ACTR controls its own promoter through E2F1. (A) HER cells were cotransfected with the indicated reporter plasmids, expression
constructs for E2F1 or ACTR, and -galactosidase. Luciferase activities were normalized with the -galactosidase activities. The putative E2F
binding sites were identified with the PROMO database (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDBTF_8.3) and are
indicated by small bars on the schematics of the pGL3-ACTR-1.6kb and -0.6kb constructs. (B) Cells were cotransfected with the pGL3-ACTR-
0.6kb reporter and an empty vector or an expression plasmid for mutant or wild-type ACTR. The structure-function domain of ACTR is shown
in the schematic, which includes moderate sequence homology to bHLH and PAS domains, protein interaction domains for E2F (EID), nuclear
hormone receptors (RID), and CBP/p300 (CID) and a region with histone acetyltransferase (HAT) activity. WT, wild type.
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ACTR-A38 containing an N-terminal truncation) showed se-
verely diminished colony formation activity. In fact, the few
colonies formed contained much fewer cells and thus were
smaller than the ones formed with wild-type ACTR (Fig. 8F).
Consistent with our previous finding that the receptor interac-
tion activity of ACTR is not involved in mediating E2F tran-
scription (32), abolishing ACTR association with the receptors
by changing the three LXXLL motifs to LXXAA in the
FIG. 7. The ACTR-E2F complex is recruited to the ACTR promoter at late G1 to stimulate its expression. (A) T98G cells were synchronized by
serum derivation and harvested at the indicated times after serum readdition for FACS and ChIP analyses. The relative occupancy at the indicated region
of the ACTR promoter was determined by quantifying the PCR products of coprecipitated genomic DNA by E2F1 and ACTR antibodies. (B, left part)
A ChIP assay was performed as for panel A with T98G cells. Coprecipitated genomic DNA from cells harvested at 18 h after serum readdition was
analyzed for occupancy by E2F1, ACTR, and RNA Pol II over the 10-kb region containing the ACTR promoter. The location of each amplicon (A to
H) is shown in the diagram above, with the number indicating the position relative to the transcription initiation site of the 5 primers used. (B, right part)
A ChIP assay was performed with asynchronously proliferating MCF7 cells, and precipitated genomic DNA was analyzed as in the left part of panel B.
(C) T98G cells were infected with adenovirus vectors to mediate the ectopic expression of ACTR (lanes A) or GFP (lanes G). Cells were harvested at
the indicated times after infection and analyzed by semiquantitative RT-PCR for ectopic or endogenous ACTR expression with specific primers (for
ectopic expression, a primer annealed to the 3 HA tag sequence 3 of the ACTR cDNA coding sequence, together with a primer to the coding region,
was used; for endogenous expression, a primer pair annealed to the cDNA sequence of the 3 untranslated region of the endogenous ACTR transcripts
was used). The relative increase shown in the right part of panel C was determined by quantifying the RT-PCR products of endogenous ACTR with the
digital number of the product from adenovirus-GFP-infected cells at 24 h set as 1 U.
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FIG. 8. Transformation of human mammary epithelial cells by overexpressed ACTR requires its association with E2F. (A) Recruitment of
ACTR and E2F1 to the ACTR promoter in MCF10A cells is stimulated by growth factors. Proliferating MCF10A cells maintained in DMEM/F12
with the full supplements (100%; details are in Materials and Methods) or changed to medium with 0.1% of the full supplements for 6 h (0.1%)
were harvested for ChIP assay with anti-ACTR or -E2F1 antibodies. ChIP DNA was analyzed for ACTR and E2F1 occupancy at the ACTR
promoter with PCR primers amplifying the F fragment as shown in Fig. 7B. (B) ACTR overexpression stimulates growth factor-independent cell
proliferation. MCF10A cells maintained in six-well plates in DMEM/F12 with the full supplementation were infected with the ACTR- or
GFP-adenovirus (Ad) vector at equal MOIs. Four hours later, the medium was changed to DMEM/F12 with 0.1% of the full supplements. On
different days after infection, cells were harvested for proliferation analysis by cell enumeration in triplicate. (D to F) Wild-type ACTR, but not
E2F association-defective mutant forms of ACTR, transforms MCF10A cells. MCF10A cells were infected with equal MOIs of adenovirus vectors
for expression of GFP or different forms of ACTR as indicated in the diagram (C), harvested 24 h after infection, resuspended as individual cells
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ACTR-AAA mutant appeared not to have any negative effect
on colony formation in either number or size (Fig. 8D and F).
These results suggest that overexpression of ACTR alone can
transform human mammary epithelial cells and that the trans-
forming activity requires the association of ACTR with E2F.
Given that MCF10A cells lack ER expression and that mutant
ACTR lacking receptor interaction possesses the same neo-
plastic transformation activity as the wild type, these results
also suggest that the transforming activity of ACTR does not
involve the ER.
DISCUSSION
Aberrant ACTR has been linked to multiple types of human
cancer. However, the function of ACTR in the control of cell
proliferation has not been well understood. In this report, we
demonstrated that ACTR is required for both normal and
malignant human cells to effectively enter S phase and that the
underlying mechanism involves the direct control of gene ex-
pressions by ACTR that are critical for initiation of DNA
replication.
ACTR functions as an important cell cycle regulator. The
E2F transcription factor family plays a key role in mammalian
cell cycle progression by controlling gene expression critical for
G1/S and G2/M transitions (22, 62, 68). Different E2Fs, in
conjunction with members of the pocket proteins, likely con-
trol a specific target gene network in a cell and tissue context-
dependent manner (6, 23, 36, 53, 61). Although it is well
understood how mitogenic signaling initiated by growth factors
impinges on the E2F-pocket protein complex to release the
transcriptional repression mediated by pRb and its family
members, little is known about the process of E2F-mediated
activation of gene expression. In this regard, our present study,
together with our previous work, strongly supports the notion
that the coactivator ACTR serves as a key mediator of the
transcriptional activation by E2Fs. We found that endogenous
ACTR associates with activators E2F1 and E2F3 but not with
repressor E2Fs such as E2F4 and is recruited to the same
region occupied by E2Fs on the E2F target genes. Its ectopic
expression drives quiescent cells to reenter the cell cycle (32).
As demonstrated in this study, the induction of ACTR recruit-
ment occurs primarily at late G1. Consistent with its timely
physical presence, we found that ACTR is required for the
expression of E2F target genes that are normally induced at
late G1 or early S phase and have important functions in the
G1-S transition (such as cyclin E and cdk2) and DNA replica-
tion (such as cdc6, cdc25A, and MCM7). Together, these find-
ings provide a mechanistic insight into the role of ACTR in the
control of the cell cycle.
Since ACTR was linked to cancer due to its overexpression,
it is possible that its function to promote cell proliferation is
manifested primarily by the aberrantly high levels of ACTR
protein in cancer cells. Indeed, Zhou et al. recently reported
that knockdown of ACTR in prostate cancer cells slowed down
cell cycle progression and decreased their proliferation (67).
Previous studies by others and us (28, 32) and the results
reported here also indicate that high levels of ACTR are re-
quired for the proliferation of malignant cells from multiple
different human cancers. Interestingly, however, when we de-
pleted the relatively low level of ACTR in normal human
fibroblast cells, we observed striking inhibitory effects on their
S-phase entry and cell cycle gene expression, indicating that
ACTR plays a critical role in the control of the cell cycle not
only in malignant cells but also in normal human cells. Lending
further support to this notion, we found that the ACTR gene
itself is cell cycle regulated, with a peak induction at the G1-S
boundary in both normal and cancerous human cells. Although
it has been shown that several transcription cofactor proteins,
including p300/CBP and PCAF, can interact with E2F, this is
the first demonstration that a cofactor can play such a unique
role in directly controlling cell cycle progression. Moreover,
consistent with our assertion that ACTR is an important cell
cycle regulator, a mouse knockout study revealed that deletion
of ACTR severely impairs the ability of mouse embryo fibro-
blasts to proliferate in response to growth factor stimulation
(60, 64).
Given the enormous complexity of cellular signaling in the
control of cell growth and differentiation, it is conceivable that
multiple sequence-specific transcription factors and cofactors
are involved in the regulation of cell cycle gene expression.
Indeed, eight members of the E2F family have been identified.
Recent studies have quickly expanded the repertoire of E2F
targets (6, 44). Interestingly, our analysis here suggests that
only a subset of the E2F targets is under the regulation of
ACTR. Thus, we found that knocking down ACTR affects the
expression of cyclins E1 and E2, cdk2, cdc6, cdc25A, and
MCM7 but not that of PCNA, RFC3, cdc45, and TopBP1 in
HeLa cells. Likewise, our recent microarray analysis revealed
that the primary effect of ACTR overexpression is on the
expression of a subset of E2F target genes involved in the G1/S
transition and DNA replication but not on genes involved in
DNA damage/checkpoint and apoptosis (unpublished data).
Since Cdc6, MCM7, and Cdc25A are required for prereplica-
tive complex formation while PCNA, RFC, and cdc45 are
involved in the transition to replication, our results imply that
ACTR is required specifically for the expression of genes crit-
ical for prereplication complex formation.
There can be many explanations for the cell- and promoter-
specific control of E2F target genes by ACTR. One of them
could be that another nuclear protein(s) modulates the asso-
ciation of ACTR with E2F and/or the assembly of E2F-ACTR
complexes at target gene loci. Several transcription factors,
mixed with soft agar, and plated for colony formation (D and F). Two weeks later, colonies (with diameters of 0.2 mm or larger) were counted
and digital images of representative fields were captured. (Note that the one colony containing about 50 cells present in the images for del-EID
and A38, respectively, was counted as a colony for the results shown in the bar graph in panel D.) The number of colonies presented was from
5  104 plated cells infected by each of the adenovirus vectors. The experiment was repeated once, and essentially identical results were obtained.
For protein analysis (E), infected cells were harvested 10 days after infection for Western blotting with anti-HA antibody or anti-ACTR antibody.
WT, wild type; IP, immunoprecipitation.
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including TFE3, YY1, and TopBP1, have been shown to play
a role in the choice of target genes by E2F (16, 17, 29, 47).
Alternatively, the cellular context dependency of ACTR may
be contributed by the multiple signal input on ACTR through
its posttranslational modifications such as phosphorylation and
acetylation (9, 12, 63). It is also possible that ACTR acts in
combination with other enzymatic complexes that modify or
remodel chromatin structure, such as CBP/p300 and the
TRRAP/Tip60 complex, to coordinate the expression of cell
cycle gene expression.
ACTR autoregulation as a mechanism of its aberrant ex-
pression or function in cancers. Elevated levels of ACTR gene
expression have been detected in an increasing number of
human cancers. Although gene amplification may account for
a small fraction of aberrant ACTR, the underlying mechanism
for ACTR overexpression in the majority of cancers has been
poorly understood. Our finding that ACTR expression is cell
cycle regulated led to our investigation of its gene regulation.
Remarkably, we found that ACTR expression is controlled not
only by E2F but also by its own protein. These results suggest
the possibility that cell cycle deregulation in the early lesion of
tumorigenesis elevates ACTR expression, which in turn en-
hances its own gene expression and accelerates cell cycle pro-
gression. This positive feedback loop could contribute to the
complete subversion of a normal cell cycle control mechanism
through the selective deregulation of a subset of E2F target
genes by elevated levels of ACTR. Indeed, the majority of
ACTR target genes we identified, including cyclin E (both E1
and E2), cyclin A2, E2F1, MCM7, and cdc25A, are often
overexpressed in many types of cancers (4, 5, 15, 50, 66).
Coelevation of ACTR with E2F1 has been found in esophageal
squamous cell carcinoma (14). Conceivably, similar findings
will be made with other types of cancer when both genes are
examined in tumor samples. As most cancer cells have accel-
erated proliferation, it is not surprising that ACTR overexpres-
sion is prevalent in a broad spectrum of human cancers. There-
fore, the positive feedback mechanism of ACTR expression
may represent a major loop that is amplified in many types of
cancers. On the other hand, the findings reported here do not
rule out other possible mechanisms, such as altered protein
stability (48, 65), that may contribute to the aberrant level of
ACTR protein found in multiple types of human cancer.
We demonstrated for the first time that overexpression of
ACTR alone can transform normal mammary epithelial cells,
suggesting that overexpressed ACTR is sufficient to trigger
events crucial for anchorage-independent growth, such as en-
hanced cell cycle progression and protection from apoptosis.
Further study is needed to understand the exact downstream
events of ACTR-mediated neoplastic transformation. In this
respect, our data are in line with the findings from animal
studies which suggest an ER-independent mechanism of
ACTR action (25, 55). Importantly, our observation that the
full transforming activity of overexpressed ACTR requires its
association with E2F directly points to the involvement of E2F.
Thus, it is plausible that aberrant ACTR up-regulates a subset
of target genes of the ACTR-E2F complex to accelerate the
cell cycle. Whether elevation of IGF-1 signaling by aberrant
ACTR, as suggested in the animal studies, or other events are
responsible for averting cells from apoptosis remains to be
determined. In any event, these results support the notion that
quantitative alteration of ACTR can result in a unique func-
tional integration of distinct transcriptional control programs,
which is ultimately responsible for the tumorigenesis associ-
ated with aberrant ACTR.
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